Latest Videos

We first report on a magnetic surface coverage assay, in which ‘large’ (2.8 μm) magnetic beads have contact with ‘small’ (1.0 μm) immobilized magnetic beads via magnetic dipolar interaction to induce specific immunocomplex formation.

This presentation will cover how bottlenecks in the validation of candidate tumour progression-related biomarkers can be overcome.

Despite extensive research effort there are no accepted clinical biomarkers that predict for response to systemic combination chemotherapy in advanced CRC.

The Imperial College London are currently aiming towards single cell measurement in microfluidic chips in combination with hydrodynamic lab-on-chip cell separation techniques, as a potentially new channel for label-free tumour cell detection in biological liquids.

This talk will illustrate, with case studies, how appropriate and timely use of imaging biomarkers can significantly reduce the risk, cost and time of drug development.

The ability to rapidly determine if a patient has an infectious disease and what type of treatment the infection will respond to, would significantly reduce the treatment decision time, shorten the impact of symptoms, and minimize transfer to others.

The High Throughput Biomedicine unit at FIMM Technology Centre provides a wide range of biomedical high throughput assays.

This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers.

Katja Arndt, University of Potsdam, speaking at Discovery Chemistry Congress 2015.